{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T10:47:19Z","timestamp":1790765239181,"version":"4.1.0"},"reference-count":42,"publisher":"Oxford University Press (OUP)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1093\/jac\/dkx107","type":"journal-article","created":{"date-parts":[[2017,3,17]],"date-time":"2017-03-17T12:11:57Z","timestamp":1489752717000},"page":"1871-1879","source":"Crossref","is-referenced-by-count":38,"title":["Adverse drug reactions during drug-resistant TB treatment in high HIV prevalence settings: a systematic review and meta-analysis"],"prefix":"10.1093","volume":"72","author":[{"given":"Kathryn","family":"Schnippel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Firnhaber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Berhanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liesl","family":"Page-Shipp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edina","family":"Sinanovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,4,16]]},"reference":[{"key":"key\n\t\t\t\t20170616061138_dkx107-B1","volume-title":"Global Tuberculosis Report","author":"WHO","year":"2016"},{"key":"key\n\t\t\t\t20170616061138_dkx107-B2","volume-title":"Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis, 2011 Update","author":"WHO","year":"2011"},{"key":"key\n\t\t\t\t20170616061138_dkx107-B3","doi-asserted-by":"crossref","first-page":"e521","DOI":"10.1097\/01.mjt.0000433951.09030.5a","article-title":"Adverse events associated with the treatment of multidrug-resistant tuberculosis: a systematic review and meta-analysis","volume":"23","year":"2016","journal-title":"Am J Ther"},{"key":"key\n\t\t\t\t20170616061138_dkx107-B4","author":"WHO","year":"2012"},{"key":"key\n\t\t\t\t20170616061138_dkx107-B5","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ijid.2014.12.045","article-title":"Health status and quality of life in tuberculosis","volume":"32","year":"2015","journal-title":"Int J Infect Dis"},{"key":"key\n\t\t\t\t20170616061138_dkx107-B6","year":"2015"},{"key":"key\n\t\t\t\t20170616061138_dkx107-B7","first-page":"1","article-title":"Programmatic management of drug-resistant tuberculosis: an updated research agenda","volume":"11","year":"2016","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20170616061138_dkx107-B8","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1093\/jac\/dks389","article-title":"Outcomes of clofazimine for the treatment of drug-resistant tuberculosis: a systematic review and meta-analysis","volume":"68","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20170616061138_dkx107-B9","doi-asserted-by":"crossref","first-page":"447","DOI":"10.5588\/ijtld.11.0451","article-title":"Linezolid for the treatment of complicated drug-resistant tuberculosis: a systematic review and meta-analysis","volume":"16","year":"2012","journal-title":"Int J Tuberc Lung Dis"},{"key":"key\n\t\t\t\t20170616061138_dkx107-B10","doi-asserted-by":"crossref","first-page":"e47370.","DOI":"10.1371\/journal.pone.0047370","article-title":"Use of anti-retroviral therapy in tuberculosis patients on second-line anti-TB regimens: a systematic review","volume":"7","year":"2012","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20170616061138_dkx107-B11","author":"US Department of Health and Human Services, NIH, NIAID, Division of AIDS","year":"2014"},{"key":"key\n\t\t\t\t20170616061138_dkx107-B12","year":"2014"},{"key":"key\n\t\t\t\t20170616061138_dkx107-B13","doi-asserted-by":"crossref","first-page":"39.","DOI":"10.1186\/2049-3258-72-39","article-title":"Metaprop: a Stata command to perform meta-analysis of binomial data","volume":"72","year":"2014","journal-title":"Arch Public Health"},{"key":"key\n\t\t\t\t20170616061138_dkx107-B14","year":"2010"},{"key":"key\n\t\t\t\t20170616061138_dkx107-B15","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1097\/QAI.0b013e31828175ed","article-title":"Adverse events in an integrated home-based treatment program for MDR-TB and HIV in KwaZulu-Natal, South Africa","volume":"62","year":"2013","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t20170616061138_dkx107-B16","doi-asserted-by":"crossref","first-page":"715","DOI":"10.4269\/ajtmh.14-0161","article-title":"Treatment outcomes for patients with multidrug-resistant tuberculosis in post-earthquake Port-au-Prince, Haiti","volume":"91","year":"2014","journal-title":"Am J Trop Med Hyg"},{"key":"key\n\t\t\t\t20170616061138_dkx107-B17","doi-asserted-by":"crossref","first-page":"e40781.","DOI":"10.1371\/journal.pone.0040781","article-title":"Adverse events among HIV\/MDR-TB co-infected patients receiving antiretroviral and second line anti-TB treatment in Mumbai, India","volume":"7","year":"2012","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20170616061138_dkx107-B18","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1080\/20786204.2012.10874288","article-title":"Adverse effects profile of multidrug-resistant tuberculosis treatment in a South African outpatient clinic","volume":"54","year":"2012","journal-title":"South African Fam Pract"},{"key":"key\n\t\t\t\t20170616061138_dkx107-B19","doi-asserted-by":"crossref","first-page":"442","DOI":"10.5588\/ijtld.15.0318","article-title":"Discordance between patient and clinician reports of adverse reactions to MDR-TB treatment","volume":"20","year":"2016","journal-title":"Int J Tuberc Lung Dis"},{"key":"key\n\t\t\t\t20170616061138_dkx107-B20","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1136\/thoraxjnl-2015-207374","article-title":"Achieving high treatment success for multidrug-resistant TB in Africa: initiation and scale-up of MDR TB care in Ethiopia-an observational cohort study","volume":"70","year":"2015","journal-title":"Thorax"},{"key":"key\n\t\t\t\t20170616061138_dkx107-B21","doi-asserted-by":"crossref","first-page":"416","DOI":"10.3201\/eid1903.120998","article-title":"Treatment outcomes for extensively drug-resistant tuberculosis and HIV co-infection","volume":"19","year":"2013","journal-title":"Emerg Infect Dis"},{"key":"key\n\t\t\t\t20170616061138_dkx107-B22","doi-asserted-by":"crossref","first-page":"14.","DOI":"10.1186\/2052-3211-7-14","article-title":"Occurrence and clinical management of moderate-to-severe adverse events during drug-resistant tuberculosis treatment: a retrospective cohort study","volume":"7","year":"2014","journal-title":"J Pharm Policy Pract"},{"key":"key\n\t\t\t\t20170616061138_dkx107-B23","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1136\/thoraxjnl-2013-203900","article-title":"High treatment success in children treated for multidrug-resistant tuberculosis: an observational cohort study","volume":"69","year":"2014","journal-title":"Thorax"},{"key":"key\n\t\t\t\t20170616061138_dkx107-B24","doi-asserted-by":"crossref","first-page":"e63057.","DOI":"10.1371\/journal.pone.0063057","article-title":"Drug-associated adverse events and their relationship with outcomes in patients receiving treatment for extensively drug-resistant tuberculosis in South Africa","volume":"8","year":"2013","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20170616061138_dkx107-B25","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1093\/cid\/ciu868","article-title":"Pharmacokinetics and safety of moxifloxacin in children with multidrug-resistant tuberculosis","volume":"60","year":"2015","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20170616061138_dkx107-B26","doi-asserted-by":"crossref","first-page":"478.","DOI":"10.1186\/s12879-015-1214-3","article-title":"Treatment outcomes in multidrug resistant tuberculosis-human immunodeficiency virus co-infected patients on anti-retroviral therapy at Sizwe Tropical Disease Hospital Johannesburg, South Africa","volume":"15","year":"2015","journal-title":"BMC Infect Dis"},{"key":"key\n\t\t\t\t20170616061138_dkx107-B27","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1086\/428582","article-title":"Treatment of multidrug-resistant tuberculosis in San Francisco: an outpatient-based approach","volume":"40","year":"2005","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20170616061138_dkx107-B28","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1097\/QAI.0b013e31821190a3","article-title":"Extensively drug-resistant TB in Eastern Cape, South Africa: high mortality in HIV-negative and HIV-positive patients","volume":"57","year":"2011","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t20170616061138_dkx107-B29","doi-asserted-by":"crossref","first-page":"979","DOI":"10.5588\/ijtld.14.0944","article-title":"Treatment of drug-resistant tuberculosis with bedaquiline in a high HIV prevalence setting: an interim cohort analysis","volume":"19","year":"2015","journal-title":"Int J Tuberc Lung Dis"},{"key":"key\n\t\t\t\t20170616061138_dkx107-B30","doi-asserted-by":"crossref","first-page":"e7186.","DOI":"10.1371\/journal.pone.0007186","article-title":"Early outcomes of MDR-TB treatment in a high HIV-prevalence setting in Southern Africa","volume":"4","year":"2009","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20170616061138_dkx107-B31","doi-asserted-by":"crossref","first-page":"e58817.","DOI":"10.1371\/journal.pone.0058817","article-title":"Serious treatment related adverse drug reactions amongst anti-retroviral na\u00efve MDR-TB patients","volume":"8","year":"2013","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20170616061138_dkx107-B32","doi-asserted-by":"crossref","first-page":"3103","DOI":"10.1093\/jac\/dku235","article-title":"Clofazimine in the treatment of extensively drug-resistant tuberculosis with HIV coinfection in South Africa: a retrospective cohort study","volume":"69","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20170616061138_dkx107-B33","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.5588\/ijtld.12.0403","article-title":"Prevalence of hypothyroidism among MDR-TB patients in Botswana","volume":"16","year":"2012","journal-title":"Int J Tuberc Lung Dis"},{"key":"key\n\t\t\t\t20170616061138_dkx107-B34","doi-asserted-by":"crossref","first-page":"468","DOI":"10.5588\/ijtld.11.0615","article-title":"High rate of hypothyroidism among patients treated for multidrug-resistant tuberculosis in Lesotho","volume":"16","year":"2012","journal-title":"Int J Tuberc Lung Dis"},{"key":"key\n\t\t\t\t20170616061138_dkx107-B35","doi-asserted-by":"crossref","first-page":"e78313.","DOI":"10.1371\/journal.pone.0078313","article-title":"High rate of hypothyroidism in multidrug-resistant tuberculosis patients co-infected with HIV in Mumbai, India","volume":"8","year":"2013","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20170616061138_dkx107-B36","doi-asserted-by":"crossref","first-page":"363.","DOI":"10.7196\/SAMJ.4964","article-title":"Aminoglycoside-induced hearing loss in HIV-positive and HIV-negative multidrug-resistant tuberculosis patients","volume":"102","year":"2012","journal-title":"S Afr Med J"},{"key":"key\n\t\t\t\t20170616061138_dkx107-B37","doi-asserted-by":"crossref","first-page":"542.","DOI":"10.1186\/1471-2334-14-542","article-title":"Successful MDR-TB treatment regimens including amikacin are associated with high rates of hearing loss","volume":"14","year":"2014","journal-title":"BMC Infect Dis"},{"key":"key\n\t\t\t\t20170616061138_dkx107-B38","first-page":"24","article-title":"Prevalence and incidence of symmetrical symptomatic peripheral neuropathy in patients with multidrug-resistant TB","volume":"104","year":"2014","journal-title":"S Afr Med J"},{"key":"key\n\t\t\t\t20170616061138_dkx107-B39","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1007\/s40264-013-0091-1","article-title":"Adverse events during treatment of drug-resistant tuberculosis: a comparison between patients with or without human immunodeficiency virus co-infection","volume":"36","year":"2013","journal-title":"Drug Saf"},{"key":"key\n\t\t\t\t20170616061138_dkx107-B40","doi-asserted-by":"crossref","first-page":"593.","DOI":"10.1186\/s12879-016-1933-0","article-title":"Severe adverse events during second-line tuberculosis treatment in the context of high HIV co-infection in South Africa: a retrospective cohort study","volume":"16","year":"2016","journal-title":"BMC Infect Dis"},{"key":"key\n\t\t\t\t20170616061138_dkx107-B41","author":"NIAID, NIH","year":"2007"},{"key":"key\n\t\t\t\t20170616061138_dkx107-B42","volume-title":"WHO Treatment Guidelines for Drug-Resistant Tuberculosis 2016","author":"WHO","year":"2016"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/72\/7\/1871\/17723538\/dkx107.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,8,24]],"date-time":"2017-08-24T20:28:12Z","timestamp":1503606492000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article-lookup\/doi\/10.1093\/jac\/dkx107"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,16]]},"references-count":42,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2017,4,16]]},"published-print":{"date-parts":[[2017,7]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkx107","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,16]]}}}